Featured Clinical Trials

  • IRB #16270: Phase I Study of Pevonedistat (TAK-924) and Decitabine Combination Therapy in High Risk Acute Myeloid Leukemia. NCT03009240
    ​PI: Guido Marcucci
     
  • IRB #17146: Phase 1 Study of SL-401 in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia (AML) or in Treatment-Naive Subjects with AML Not Eligible for Standard Induction Therapy or in Subjects with High-Risk Myelodysplastic Syndrome (MDS). NCT03113643
    PI: Anthony Stein
     
  • IRB #13447: Phase I Study to Evaluate Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients with High-Risk CD19+ Acute Lymphoblastic Leukemia. NCT02146924 
    PI: Samer Khaled
     
  • IRB #17135: A phase 1/2 trial evaluating the safety and tolerability of pembrolizumab when given as monotherapy or in combination with blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia (Opening Soon).
    PI: Elizabeth Budde
     
  • IRB #13272: Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients with CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm. NCT02159495
    PI: Elizabeth Budde
     
  • IRB #17147: A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia. NCT02890329
    PI: Samer Khaled